/Investor DB

Evidity Health Capital — 2026 Investments

2 investments dated 2026 · listed companies and verified rows first · show all

GammaTilegammatile.comin𝕏Jun 2026 · $100M

GammaTile is an FDA-cleared, bioresorbable collagen tile embedded with radiation sources that is implanted during brain tumor removal surgery to deliver targeted radiation to remaining cancer cells.

BiotechHealthtechMedical Devices

David G. Brachman, MD, FASTRO(Co-Founder and Chief Technology Officer)Heyoung McBride, MD, MS, FASTRO(Co-Founder)Peter Nakaji, MD(Co-Founder)inEmad Youssef, MD(Co-Founder)Theresa Thomas, MS, CCRC(Co-Founder)Per Langoe(Chief Executive Officer)in

Co-investorsAccelmed PartnersBlueStone Venture PartnersFemHealth VenturesGilde HealthcareMedTech Venture PartnersMVM Life Science Partners+1 more

Other

Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.

GT Medical Technologies

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.